Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.66 |
| ▸ | CCR5 | P51681 | 1/20 | 0.66 |
| ▸ | NR3C1 | P04150 | 9/20 | 0.48 |
| ▸ | SPR | P35270 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5961458 | 0.86 | CCR2 (0.68) | CCR2CCR5NR3C1SPRPOLB | |
| SCHEMBL5961447 | 0.85 | CCR2 (0.59) | CCR2CCR5NR3C1SPRPOLB | |
| SCHEMBL7079541 | 0.83 | CCR2 (0.68) | CCR2CCR5NR3C1SPRPOLB | |
| SCHEMBL5961441 | 0.83 | CCR2 (0.59) | CCR2CCR5NR3C1SPRPOLB | |
| SCHEMBL5961571 | 0.83 | CCR2 (0.59) | CCR2CCR5NR3C1SPRPOLB | |
| SCHEMBL5961527 | 0.81 | CCR2 (0.57) | CCR2CCR5NR3C1SPRPOLB | |
| SCHEMBL17980518 | 0.81 | NR3C1 (0.71) | CCR2CCR5NR3C1SPRPOLB | |
| SCHEMBL7079323 | 0.80 | CCR2 (0.66) | CCR2CCR5NR3C1SPRPOLB | |
| SCHEMBL18841095 | 0.80 | CCR2 (1.00) | CCR2CCR5NR3C1SPRPOLB | |
| SCHEMBL8574855 | 0.79 | SPR (0.61) | CCR2CCR5NR3C1SPRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670364-B2 | For example (1,3-dimethylpyrazolo(5,4-b)pyridin-5-yl)-N-(((4-fluorophenyl) amino)carbonyl)-carboxamide; useful in prevention or treatment of chronic or acute inflammatory or autoimmune diseases | TELIK, INC. | 2003-12-30 | — | — | US | claimed |
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-05-22 | — | — | US | claimed |
| US-6992086-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-6670364-B2 | For example (1,3-dimethylpyrazolo(5,4-b)pyridin-5-yl)-N-(((4-fluorophenyl) amino)carbonyl)-carboxamide; useful in prevention or treatment of chronic or acute inflammatory or autoimmune diseases | TELIK, INC. | 2003-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | CCR2 1/4885CCR5 4/4885NR3C1 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.